DE69927369D1 - Hemmung xenoreaktiver antikörper - Google Patents

Hemmung xenoreaktiver antikörper

Info

Publication number
DE69927369D1
DE69927369D1 DE69927369T DE69927369T DE69927369D1 DE 69927369 D1 DE69927369 D1 DE 69927369D1 DE 69927369 T DE69927369 T DE 69927369T DE 69927369 T DE69927369 T DE 69927369T DE 69927369 D1 DE69927369 D1 DE 69927369D1
Authority
DE
Germany
Prior art keywords
xenoantigen
xenopolymer
antibodies
host
xenograft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927369T
Other languages
English (en)
Other versions
DE69927369T2 (de
Inventor
Alexander Schwarz
A Davis
E Diamond
S Logan
W Byrne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of DE69927369D1 publication Critical patent/DE69927369D1/de
Publication of DE69927369T2 publication Critical patent/DE69927369T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
DE69927369T 1998-04-15 1999-04-15 Hemmung xenoreaktiver antikörper Expired - Fee Related DE69927369T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6052598A 1998-04-15 1998-04-15
PCT/US1999/008326 WO1999052561A1 (en) 1998-04-15 1999-04-15 Inhibition of xenoreactive antibodies
US60525 2002-01-29

Publications (2)

Publication Number Publication Date
DE69927369D1 true DE69927369D1 (de) 2006-02-02
DE69927369T2 DE69927369T2 (de) 2006-06-22

Family

ID=22030043

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69927369T Expired - Fee Related DE69927369T2 (de) 1998-04-15 1999-04-15 Hemmung xenoreaktiver antikörper
DE1087791T Pending DE1087791T1 (de) 1998-04-15 1999-04-15 Hemmung xenoreaktiver antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1087791T Pending DE1087791T1 (de) 1998-04-15 1999-04-15 Hemmung xenoreaktiver antikörper

Country Status (10)

Country Link
US (3) US6572867B1 (de)
EP (1) EP1087791B1 (de)
JP (1) JP2002511431A (de)
AT (1) ATE304865T1 (de)
AU (1) AU761831B2 (de)
CA (1) CA2326618A1 (de)
DE (2) DE69927369T2 (de)
ES (1) ES2249890T3 (de)
HK (1) HK1036223A1 (de)
WO (1) WO1999052561A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2173500A (en) * 1998-12-09 2000-06-26 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
WO2001051499A1 (en) * 2000-01-13 2001-07-19 Alchemia Pty Ltd METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES
US7270961B2 (en) * 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20060099169A1 (en) * 2004-10-13 2006-05-11 Ilypsa, Inc. Toxin binding compositions
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
US8450068B2 (en) 2007-02-16 2013-05-28 University Of Virginia Patent Foundation IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis
EP2095829A1 (de) * 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenhaltige Modifizierungsmittel und Konjugate
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011139488A2 (en) 2010-05-06 2011-11-10 Mayo Foundation For Medical Education And Research Methods and materials for reducing cardiac xenograft rejection
US20130149331A1 (en) * 2011-05-03 2013-06-13 Peng George Wang Rhamnose and forssman conjugated immunogenic agents
US9533214B2 (en) 2012-09-25 2017-01-03 Igt Gaming system and method for providing plays of multiple games
EP3116887B1 (de) 2014-03-13 2021-02-17 Universität Basel Carbohydrat-liganden, die an gegen myelin-assoziertes -glukoprotein igm-antikörper binden
EP2987503A1 (de) * 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Verfahren und Reagenzien zur Prävention und/oder Behandlung von Infektionen
CN107106607A (zh) 2014-10-22 2017-08-29 印第安纳大学研究与技术公司 适用于异种移植的三重转基因猪
EP3350193B1 (de) 2015-09-16 2020-12-23 Universität Basel An antikörper gegen glycoepitope von glycosphingolipiden bindende kohlenhydratliganden

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8001748L (sv) * 1980-03-05 1981-09-06 Kaellenius Gunilla Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5651968A (en) * 1991-08-23 1997-07-29 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US5879675A (en) * 1994-03-15 1999-03-09 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising α-galactosyl epitopes
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
USRE39245E1 (en) * 1995-12-21 2006-08-22 Procur Ab Galactopyranosides and their use
AU6319198A (en) * 1997-02-05 1998-08-25 Biotransplant Incorporated Induction of b cell tolerance
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
DE69835201T2 (de) * 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents

Also Published As

Publication number Publication date
CA2326618A1 (en) 1999-10-21
US20040141944A1 (en) 2004-07-22
AU3564599A (en) 1999-11-01
WO1999052561A1 (en) 1999-10-21
EP1087791A1 (de) 2001-04-04
ES2249890T3 (es) 2006-04-01
EP1087791B1 (de) 2005-09-21
US6572867B1 (en) 2003-06-03
DE1087791T1 (de) 2002-02-21
AU761831B2 (en) 2003-06-12
DE69927369T2 (de) 2006-06-22
ATE304865T1 (de) 2005-10-15
JP2002511431A (ja) 2002-04-16
HK1036223A1 (en) 2001-12-28
US20080124396A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
ATE304865T1 (de) Hemmung xenoreaktiver antikörper
Huter et al. TGF‐β‐induced Foxp3+ regulatory T cells rescue scurfy mice
PT892643E (pt) Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
EA199901046A1 (ru) Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантанта
ES2143642T3 (es) Fibras inorganicas.
ATE261314T1 (de) P53 impfstoff
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
WO1992021724A3 (de) Unter abspaltung von alkoholen zu elastomeren vernetzbare organo(poly)siloxanmassen
Haisch et al. A glycoprotein from Schistosoma mansoni eggs binds non‐antigen‐specific immunoglobulin E and releases interleukin‐4 from human basophils
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
Lee et al. Immune responses of cattle to biochemically modified antigens from the midgut of the cattle tick, Boophilus microplus
DK0728016T3 (da) Anvendelse af anti-idiotypiske antistoffer til forebyggelse af hyperakut afstødning af xenotransplantater
FI945177A (fi) Vinyylioksiryhmiä sisältävät siloksaanisekapolymeerit, niiden valmistus ja käyttö
EP1028754A4 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DK0782630T3 (da) Polycystisk nyresygdomsgen
King et al. Schistosoma mansoni: protective immunity in IL-4-deficient mice
MY103580A (en) Acaricide formulations
Kassis et al. Echinococcus multilocularis: complement's role in vivo in hydatid disease
Glaser et al. Inhibitory effect of α-globulin on the second set allograft reaction
Lee et al. The effect of lyophilization on graft acceptance in experimental xenotransplantation using porcine cornea
Ladds et al. Animal model of human disease. Squamous cell carcinoma. Ovine squamous cell carcinoma.
Manez et al. Neutralization of anti-aGalactosyl antibodies without immunosuppression prevents hyperacute rejection but not acute vascular rejection of pig organs transplanted into baboons
IM et al. MODIFICATION OF GRAFT-VERSUS-HOST DISEASE BY NEURAMINIDASE TREATMENT OF DONOR CELLS DECREASED TOLEROGENICITY OF NEURAMINIDASE-TREATED CELLS
Tsoi et al. Mechanisms of immunity to Sarcoma I allografts in the C57BL/Ks mouse. II. Passive transfer studies with immune serum in X-irradiated hosts
NO981718L (no) Blanding for behandling av fjµrfestr°

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee